Credit Suisse Group began coverage on shares of Spark Therapeutics (NASDAQ:ONCE) in a research note issued to investors on Wednesday, January 17th, Marketbeat reports. The firm issued an outperform rating and a $61.00 price objective on the biotechnology company’s stock.
Other analysts have also recently issued research reports about the company. SunTrust Banks set a $101.00 target price on Spark Therapeutics and gave the stock a buy rating in a report on Monday, October 16th. BMO Capital Markets set a $89.00 target price on Spark Therapeutics and gave the stock a buy rating in a report on Tuesday, October 10th. Cowen restated a buy rating and set a $95.00 target price on shares of Spark Therapeutics in a report on Tuesday, October 10th. Jefferies Group reiterated a buy rating and issued a $95.00 price target on shares of Spark Therapeutics in a report on Tuesday, October 10th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $105.00 price target (up previously from $94.00) on shares of Spark Therapeutics in a report on Tuesday, October 10th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eighteen have assigned a buy rating to the stock. Spark Therapeutics currently has a consensus rating of Buy and a consensus target price of $73.73.
Spark Therapeutics (NASDAQ:ONCE) opened at $54.08 on Wednesday. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75. The stock has a market capitalization of $2,000.00, a price-to-earnings ratio of -7.51 and a beta of 3.02.
In related news, CFO Stephen W. Webster sold 10,000 shares of Spark Therapeutics stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $70.14, for a total value of $701,400.00. Following the sale, the chief financial officer now owns 12,500 shares of the company’s stock, valued at approximately $876,750. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total value of $356,600.00. Following the transaction, the insider now directly owns 215,000 shares in the company, valued at approximately $15,333,800. The disclosure for this sale can be found here. In the last three months, insiders sold 15,018 shares of company stock worth $1,058,834. 7.30% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of ONCE. Ameritas Investment Partners Inc. boosted its stake in shares of Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 389 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Spark Therapeutics during the 2nd quarter worth approximately $143,000. Public Employees Retirement Association of Colorado bought a new position in shares of Spark Therapeutics during the 4th quarter worth approximately $163,000. BNP Paribas Arbitrage SA boosted its stake in shares of Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 2,449 shares during the period. Finally, Aperio Group LLC boosted its stake in shares of Spark Therapeutics by 29.2% during the 4th quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 898 shares during the period. Institutional investors own 95.87% of the company’s stock.
WARNING: “Spark Therapeutics (NASDAQ:ONCE) Research Coverage Started at Credit Suisse Group” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/13/spark-therapeutics-once-research-coverage-started-at-credit-suisse-group.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.